The ThT endpoint fluorescence intensity of sTau-SAA was dramatically higher in AD than in synucleinopathies, whereas the skin-tau fluorescence intensity was also significantly increased in synucleinopathies except for MSA than in the control group (Fig. 4), consistent with the previous observations that some of cases with synucleinopathies can have tau-pathology [23, 25–27]. The gene discussed is MAPT; the disease is Alzheimer disease.